News & Events
January 23, 2012
European Medicines Agency Deems Imaging Biomarker a Qualified Measure to Select Patients with Early Stages of Cognitive Impairment for Alzheimer’s Disease Clinical TrialsBased on a request for regulatory review by Critical Path Institute’s (C-Path) Coalition Against Major Diseases (CAMD), the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use has issued a positive opinion on the use of magnetic resonance imaging (MRI) to measure hippocampal volume as a tool to enrich recruitment into regulated clinical......
October 17, 2011
Critical Path Institute and Clinical Data Interchange Standards Consortium Announce Release of Data Standards for Alzheimer’s Disease ResearchCritical Path Institute(C-Path)and Clinical Data Interchange Standards Consortium(CDISC) today announced the release of version 1.0 of the Alzheimer’s disease (AD) Therapeutic Area Standard(SDTM AD/Mild Cognitive Impairment User Guide). This was developed for the clinical research community to facilitate analysis and learning from clinical studies for treatment or prevention of AD....
December 10, 2010
Executive director of Critical Path Institute’s Coalition Against Major Diseases testifies before congress on Alzheimer’s disease progressMarc Cantillon, MD, presents the critical role of public/private partnerships in creating innovative tools to advance the development of new Alzheimer’s disease...
June 10, 2010
Coalition Against Major Diseases Introduces the First Combined Pharmaceutical Trial Data on Neuro-degenerative DiseasesA new database of more than 4,000 Alzheimer’s disease patients who have participated in 11 industry-sponsored clinical trials will be released today by the Coalition Against Major Diseases (CAMD)....